Initiating Titratable Fixed-Ratio Combinations of Basal Insulin Analogs and Glucagon-Like Peptide-1 Receptor Agonists: What You Need to Know-Reference-Cited by-同舟云学术

Initiating Titratable Fixed-Ratio Combinations of Basal Insulin Analogs and Glucagon-Like Peptide-1 Receptor Agonists: What You Need to Know

Published:2018-04-01 Issue:2 Volume:36 Page:174-182
ISSN:0891-8929
Container-title:Clinical Diabetes
language:en
Short-container-title:

Author:

Skolnik Neil¹,Hinnen Debbie²,Kiriakov Yan¹,Magwire Melissa L.³,White John R.⁴

Affiliation:

1. Abington Jefferson Health, Abington, PA

2. Memorial Hospital Diabetes Center, Colorado Springs, CO

3. Shawnee Mission Health, Merriam, KS

4. Washington State University, Spokane, WA

Abstract

IN BRIEF Titratable fixed-ratio combinations (FRCs) of a basal insulin and a glucagon-like peptide-1 (GLP-1) receptor agonist are new therapeutic options for people with type 2 diabetes. Two FRCs—insulin degludec/liraglutide and insulin glargine/lixisenatide—have been approved for use in the United States. The two components in these FRCs target different aspects of diabetes pathophysiology, working in a complementary manner to decrease blood glucose while mitigating the side effects associated with each component (hypoglycemia and weight gain with insulin and gastrointestinal side effects with GLP-1 receptor agonists). This article reviews these products and key considerations for their use.

Publisher

American Diabetes Association

Subject

Endocrinology, Diabetes and Metabolism,Internal Medicine

Link

https://diabetesjournals.org/clinical/article-pdf/36/2/174/500795/174.pdf

Reference64 articles.

1. World Health Organization . Global report on diabetes: executive summary. Available from http://apps.who.int/iris/bitstream/10665/204874/1/WHO_NMH_NVI_16.3_eng.pdf. Accessed 28 September 2017

2. National Diabetes Statistics Report, 2017: Estimates of Diabetes and Its Burden in the United States;Centers for Disease Control and Prevention,2017

3. 10-year follow-up of intensive glucose control in type 2 diabetes;Holman;N Engl J Med,2008

4. DCCT/EDIC Research Group. Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications study at 30 years: advances and contributions;Nathan;Diabetes,2013

5. Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach. Update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes;Inzucchi;Diabetes Care,2015

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Treatment intensification following glucagon-like peptide-1 receptor agonist in type 2 diabetes: Comparative effectiveness analyses between free vs. fixed combination of GLP-1 RA and basal insulin. RESTORE-G real-world study;Nutrition, Metabolism and Cardiovascular Diseases;2024-08

2. Efficacy and Durability of Combination Treatment With Glucagon-Like Peptide-1 Receptor Agonists and Basal Insulin;ADCES in Practice;2022-10-01

3. Treatment persistence and adherence in people with type 2 diabetes switching to iGlarLixi vs free-dose combinations of basal insulin and glucagon-like peptide 1 receptor agonist;Journal of Managed Care & Specialty Pharmacy;2022-09

4. Practical Guidance on Basal Insulin Initiation and Titration in Asia: A Delphi-Based Consensus;Diabetes Therapy;2022-06-29

5. Translating iGlarLixi Evidence for the Management of Frequent Clinical Scenarios in Type 2 Diabetes;Advances in Therapy;2021-02-23